In a recent study comparing protein profiles between breast cancer patients and controls, it was also shown that plasma apoC-I was lower in affected patients, and further analyses identified apoC-I signature peptides able to inhibit breast cancer cell proliferation in vitro [15]. Here, APOC1 is linked to breast carcinoma.